Oct 14, 2020

Report: Eli Lilly halts COVID-19 treatment trial

Posted by in categories: biotech/medical, government

Eli Lilly (NYSE: LLY) reportedly paused a clinical trial testing its COVID-19 antibody treatment candidate because of a “potential safety concern.”

The New York Times reported that Eli Lilly’s testing site researchers were notified of the pause by emails sent by government officials (it is a government-sponsored trial) and the company later confirmed it. A spokesperson from the company told The Hill that “Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment.”

Eli Lilly’s trial was comparing its therapy to a placebo, while all study participants also received the experimental drug remdesivir, which has been used in treating COVID-19 throughout the pandemic. The company’s therapeutic uses monoclonal antibodies in an effort to block the virus from infecting cells.

Leave a reply